Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)
| Market Cap | $6.59M-83.3% |
| Revenue (ttm) | $0 |
| Net Income | -$19.68M-42.9% |
| EPS | -$9.15+99.0% |
| Shares Out | 2.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,312 |
| Open | $3.50 |
| Previous Close | $3.36 |
| Day's Range | $3.18 - $3.54 |
| 52-Week Range | $3.18 - $23.50 |
| Beta | 1.64 |
| Analysts | Buy |
| Price Target | $17.00(+418.29%) |
| Earnings Date | Mar 25, 2027 |
About QNRX
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. Stock Analysis — InsiderScore
Quoin Pharmaceuticals, Ltd. scored higher than 10% of companies evaluated by InsiderBuying, and ranked 78th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Quoin Pharmaceuticals, Ltd. bought $280.0K of stock across 4 purchases in the last 90 days, the largest of them $100.0K.
The average purchase added about 79% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 25, 2027Earnings report
$QNRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in QNRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by QNRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
QNRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New QNRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to QNRX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from QNRX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-11.9 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
